Vertex Pharmaceuticals (VRTX) Projected to Post Earnings on Thursday

Vertex Pharmaceuticals (NASDAQ:VRTX) is expected to be announcing its Q4 2025 results after the market closes on Thursday, February 12th. Analysts expect the company to announce earnings of $5.05 per share and revenue of $3.1762 billion for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 12, 2026 at 4:30 PM ET.

Vertex Pharmaceuticals Stock Down 1.6%

Shares of VRTX stock opened at $463.48 on Wednesday. The company has a 50 day moving average price of $459.15 and a 200-day moving average price of $427.05. Vertex Pharmaceuticals has a 52 week low of $362.50 and a 52 week high of $519.68. The firm has a market capitalization of $117.59 billion, a PE ratio of 32.69 and a beta of 0.30.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Charles F. Wagner, Jr. sold 14,000 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $456.00, for a total transaction of $6,384,000.00. Following the transaction, the executive vice president owned 37,725 shares of the company’s stock, valued at $17,202,600. The trade was a 27.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Ourania Tatsis sold 4,500 shares of the stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $474.99, for a total transaction of $2,137,455.00. Following the completion of the sale, the executive vice president directly owned 42,293 shares of the company’s stock, valued at approximately $20,088,752.07. This trade represents a 9.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 165,105 shares of company stock worth $73,858,523. 0.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of VRTX. CYBER HORNET ETFs LLC increased its stake in Vertex Pharmaceuticals by 4.0% in the 3rd quarter. CYBER HORNET ETFs LLC now owns 695 shares of the pharmaceutical company’s stock worth $272,000 after buying an additional 27 shares in the last quarter. PGIM Custom Harvest LLC boosted its stake in shares of Vertex Pharmaceuticals by 2.3% in the third quarter. PGIM Custom Harvest LLC now owns 1,248 shares of the pharmaceutical company’s stock worth $489,000 after acquiring an additional 28 shares during the period. ICW Investment Advisors LLC grew its position in shares of Vertex Pharmaceuticals by 5.0% during the second quarter. ICW Investment Advisors LLC now owns 604 shares of the pharmaceutical company’s stock worth $269,000 after purchasing an additional 29 shares in the last quarter. Strategic Investment Advisors MI raised its stake in Vertex Pharmaceuticals by 2.2% during the 2nd quarter. Strategic Investment Advisors MI now owns 1,774 shares of the pharmaceutical company’s stock valued at $788,000 after purchasing an additional 39 shares during the period. Finally, Larson Financial Group LLC raised its stake in Vertex Pharmaceuticals by 6.4% during the 3rd quarter. Larson Financial Group LLC now owns 863 shares of the pharmaceutical company’s stock valued at $338,000 after purchasing an additional 52 shares during the period. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Analyst Upgrades and Downgrades

VRTX has been the subject of a number of research reports. Royal Bank Of Canada upgraded shares of Vertex Pharmaceuticals from a “sector perform” rating to an “outperform” rating and boosted their target price for the company from $455.00 to $546.00 in a research note on Thursday, January 22nd. Sanford C. Bernstein raised Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, January 12th. Weiss Ratings raised Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, February 4th. Barclays raised Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $414.00 to $606.00 in a research report on Tuesday, January 27th. Finally, Leerink Partners increased their price objective on shares of Vertex Pharmaceuticals from $456.00 to $525.00 and gave the stock an “outperform” rating in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $522.68.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.